Relief Cardiovascular, a private medical technology company developing the Relief system, a transcatheter implant designed to intelligently monitor and modulate cardiac preload to relieve congestion in heart failure, has announced the appointment of Harry Rowland as chairman of the board.
Rowland served as the chief executive officer of Endotronix, a medical device company he co-founded that developed the Cordella pulmonary artery (PA) sensor system. Under his leadership, Endotronix advanced the technology through pivotal study completion, commercial approval, and ultimately its acquisition by Edwards Lifesciences in 2024.
“Harry is a remarkable leader who guided Endotronix from napkin sketch to commercial approval and exit,” said Alex Cooper, chief executive officer of Relief Cardiovascular. “His leadership experience, domain expertise, and understanding of the clinical and operational complexities of remote management make him an exceptional fit for Relief as we expand the Relief system into broader clinical evaluation. I’m excited to work alongside Harry—his guidance will accelerate our journey and strengthen our ability to deliver meaningful benefit to patients.”
“One of the most fundamental challenges in heart failure is controlling congestion,” said Harry Rowland. “Relief’s approach to drive decongestion while protecting the kidneys has the potential to address a critical need in heart failure care. I’m thrilled to support the company as it works to deliver a scalable and clinically meaningful solution for patients and clinicians battling heart failure congestion.”
